Biotechnology
EXCLUSIVE: Harmony Biosciences’ CEO, Jeffrey Dayno, on Innovation and Expanding Patient Impact
Stoxpo: Harmony Biosciences has shown strong growth with WAKIX. What factors are behind this performance? Jeffrey Dayno: Our growth is...
Weight-Loss Battle Heats Up: GLP-1 Pills Could Challenge Novo Nordisk and Eli Lilly’s Dominance
As new GLP-1 oral pills enter the market, competition rises to challenge established injectables, sparking hope and concern over side...
BCYC’s Promising Oncology Pipeline: Updates Highlight Strong Efficacy and Tolerability in Key Cancer Trials
Encouraging Data Supports Advancements in Novel Cancer Therapeutics BCYC (Bicycle Therapeutics) is continuing to make significant strides in the development...
Eli Lilly to Invest $1.8 Billion in Expanding Manufacturing for Alzheimer’s, Diabetes, and Obesity Treatments in Ireland
Major investments in Limerick and Kinsale will help meet soaring demand for key drugs Eli Lilly (LLY) has announced plans...
Advancements in EGFR-Targeted Therapies: Promising Phase 1b Data for Firmonertinib in NSCLC Patients with Rare EGFR Mutations
Novel treatments show potential in addressing hard-to-treat mutations in lung cancer, bringing hope for improved outcomes ArriVent Biopharma recently unveiled...
Summit Therapeutics Announces Promising Phase III Trial Results for Ivonescimab in Lung Cancer
First-line treatment shows significant improvement in progression-free survival over pembrolizumab, marking a potential shift in NSCLC care Summit Therapeutics (SMMT)...
SYRE’s Innovative Biologics: A Game-Changer in Inflammatory Bowel Disease Treatment
Targeting Leading IBD Pathways, SYRE Aims to Redefine Efficacy and Convenience with Next-Generation Antibodies SYRE (SYRE), a clinical-stage biopharmaceutical company,...
Why Are These Stocks Surging Today?
Examining the Unprecedented Moves of Windtree Therapeutics, Regencell Therapeutics, and Coursera In the ever-fluctuating stock market, certain companies stand out...
Viking Therapeutics Advances Multiple Therapies Amid Strong Clinical Progress and Financial Stability
Obesity Drug VK2735 to Enter Phase 3, NASH Therapy VK2809 Shows Promising Results, and Novel Treatments in Development Viking Therapeutics...
Future Directions in Obesity Treatment: Survey Insights and Innovations
Exploring New Frontiers in Effective Weight Management Obesity continues to be a pressing global health issue, necessitating the continual evolution...
